In conclusion, this analysis confirms and strengthens existing literature (pretty high frequency of ARID1A alterations among solid tumors, especially particular subtypes of gynecological cancers, higher value of TMB, poorest outcomes among ARID1A+ cancers, no predictive role for platinum-based chemotherapy). The gene discussed is ARID1A; the disease is cancer.